Bumble Agrees to $1.3 Billion Take-Private Acquisition by Ithaca Holdings
Shareholders receive $6.05 per share, a 138% premium.
Already have an account? Sign in.
Shareholders receive $6.05 per share, a 138% premium.
Generate Biomedicines receives $30M upfront in a deal with Zealand Pharma to advance AI protein candidates for obesity, up to $1.2B total.
Early Phase 1 data for Biomea’s oral GLP-1 showed limited weight reduction versus expectations, leading investors to sell the stock and management to seek a partner.
CEO Dickerson expressed strong confidence in AI-driven growth but stopped short of a firm wafer fab equipment forecast amid factory and supply limits.
Be the first to know when deals break, stocks move, or biotech headlines hit.